FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview

Cancers

Christine Schmitz¹  Peter Borchmann²  Conrad-Amadeus Voltin³  Jasmin Mettler³  Markus Dietlein³  Carsten Kobe³  Jirka Grosse⁴  Dirk Hellwig⁴  Christian Baues⁵ 

[1] Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany;Department of Internal Medicine I, Center for Integrated Oncology Aachen-Bonn-Cologne-Dusseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany;Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany;Department of Nuclear Medicine, University Hospital Regensburg, 93053 Regensburg, Germany;Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany;

关键词: hodgkin lymphoma;    diffuse large b-cell lymphoma;    positron emission tomography;    staging;    response assessment;   

DOI  :  10.3390/cancers12030601

来源: DOAJ

【 摘 要 】

Since the mid-1990s, ¹⁸F-fluorodeoxglucose (FDG)-positron emission tomography (PET) in combination with computed tomography has come to play a prominent role in the management of malignant lymphomas. One of the first PET applications in oncology was the detection of lymphoma manifestations at staging, where it has shown high sensitivity. Nowadays, this imaging modality is also used during treatment to evaluate the individual chemosensitivity and adapt further therapy accordingly. If the end-of-treatment PET is negative, irradiation in advanced-stage Hodgkin lymphoma patients can be safely omitted after highly effective chemotherapy. Thus far, lymphoma response assessment has mainly been performed using visual criteria, such as the Deauville five-point scale, which became the international standard in 2014. However, novel measures such as metabolic tumor volume or total lesion glycolysis have recently been recognized by several working groups and may further increase the diagnostic and prognostic value of FDG-PET in the future.

【 授权许可】

Unknown